Xtandi’s Success A Double-Edged Sword
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas/Medivation prostate cancer drug is the latest focus of drug pricing criticism in the news but it doesn’t seem likely that NIH will grant open licenses on the drug’s patent under its “march-in” authority, as legislators and advocacy groups request.
You may also be interested in...
NIH Resists “March In” On Norvir Patents Based On Pricing Concerns
NIH will not invoke its “march-in” authority under the Bayh-Dole Act to allow broader access to Norvir patents, Director Francis Collins says in response to a petition.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.